Based on the beneficial ownership of our common stock as of December 31, 2019, prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately % of our voting stock and, upon the completion of this offering, that same group will hold approximately % of our outstanding voting stock (assuming no exercise of the underwriters option to purchase additional shares, no exercise of outstanding options or warrants and no purchases of shares in this offering by any of this group), in each case assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock and the net exercise of warrants outstanding that would otherwise expire upon the completion of this offering
GHK-Cu provides the peptide support your skin cells need daily
The headliner is BPC-157, a substance whose PubMed footprint now runs north of two hundred papers
Phase 4 (Weeks 13+): Consider complex combinations like the GLOW protocol ONLY after confirming you can tolerate each individual component
Timeline: Some peptides (like BPC-157 for injuries) may show effects within weeks, while others (like GHK-Cu for collagen synthesis) work over months
Additionally, research shows Ipamorelins ability to influence IGF-1 levels through growth hormone release further supports its role in growth and metabolic research
